wuhan
institut
virolog
decis
made
midst
rapidli
escal
health
crisi
claim
right
unproven
use
drug
heavili
criticis
worth
note
wuhan
institut
virolog
patent
applic
file
scientist
start
experi
investig
effect
remdesivir
effect
wuhan
institut
virolog
first
vitro
studi
suggest
remdesivir
antimalari
drug
call
chloroquin
could
effect
inhibit
publish
earli
februari
earliest
phase
studi
remdesivir
patient
start
public
studi
given
scale
pandem
one
would
expect
virolog
institut
locat
origin
epicentr
devot
resourc
energi
contain
spread
underli
viru
perhap
research
new
therapi
vaccinesnot
patent
supposedli
new
use
drug
neither
develop
test
though
legal
admiss
wuhan
institut
virolog
decis
seek
patent
case
ethic
question
may
neg
impact
china
public
health
medic
research
cooper
effort
respons
public
outcri
wuhan
institut
virolog
defend
patent
applic
claim
made
nation
interest
ad
would
will
forgo
enforc
patent
right
foreign
pharmaceut
companiesin
case
gileadcollabor
chines
author
stop
pandem
argument
weak
wuhan
institut
virolog
realli
concern
public
health
access
vital
drug
emerg
alreadi
mechan
give
countri
intellectu
properti
ip
flexibl
event
compulsori
licens
controversi
compulsori
licens
allow
elig
drugmak
legal
manufactur
sell
copycat
version
patent
drug
nation
emerg
public
health
crise
instanc
extrem
need
form
compens
origin
patent
holder
compet
authorityin
china
case
would
nation
intellectu
properti
administrationwould
requir
manufactur
pay
fair
market
price
drug
compulsori
licenc
explicitli
allow
articl
chines
patent
law
although
countri
yet
issu
one
line
world
trade
organ
wto
traderel
aspect
intellectu
properti
right
trip
agreement
outlin
global
standard
protect
ip
right
doha
declar
trip
agreement
public
health
adopt
wto
ministeri
confer
confirm
compulsori
licenc
use
subject
certain
condit
grant
led
w
haiyun
china
begin
test
ebola
drug
coronaviru
patient
sixth
tone
februari
http
signific
reduct
drug
price
exampl
indian
gener
drugmak
natco
grant
compulsori
licenc
sorafenib
anticanc
drug
countri
patent
offic
rule
bayer
ag
sorafenib
patent
holder
done
enough
make
drug
avail
indian
citizen
natco
requir
pay
royalti
german
companya
figur
base
unit
nation
un
guidelin
propos
sell
version
bayer
price
given
scale
ongo
health
crisi
chines
compani
file
compulsori
licenc
would
necessarili
perceiv
attempt
unjustifi
circumv
gilead
patent
right
wake
coronaviru
crisi
march
israel
issu
compulsori
licenc
relat
kaletra
hiv
medicin
current
test
effect
treatment
patent
own
us
pharmaceut
compani
abbvi
licenc
allow
israel
import
gener
version
kaletra
produc
indian
compani
hetero
addit
chilean
parliament
ecuador
nation
assembl
adopt
resolut
would
pave
way
issuanc
compulsori
licenc
tackl
coronaviru
outbreak
german
govern
start
plan
limit
patent
right
view
pandem
north
american
canada
also
follow
lead
unusu
strategi
wuhan
institut
virolog
settl
onseek
patent
untest
use
drug
way
might
interfer
patent
right
own
foreign
corporationha
rais
hackl
critic
accus
institut
tri
get
pay
gilead
licenc
fee
compulsori
licens
grant
other
read
move
attempt
secur
bargain
chip
possibl
upcom
price
negoti
compani
anoth
chines
entiti
come
fire
patent
advoc
suzhoubas
brightgen
biomed
technolog
may
also
fight
confirm
synthesis
remdesivir
activ
ingredi
without
first
obtain
permiss
patent
holder
though
compani
say
interest
set
voluntari
licens
agreement
gilead
point
futur
also
claim
work
infring
compani
patent
right
final
product
sold
market
highli
debat
inde
intern
nation
patent
law
manufactur
patent
medicin
even
yet
sale
still
amount
patent
infring
real
risk
strategi
adopt
wuhan
institut
virolog
brightgen
particular
may
rais
intern
compani
suspicion
regard
chines
peer
turn
may
hamper
vital
research
cooper
china
world
gilead
exampl
offer
sampl
remdesivir
use
clinic
trial
current
outbreak
lead
intern
pharmaceut
firm
current
work
vaccin
johnson
johnson
glaxosmithklin
may
less
incent
futur
believ
china
support
ip
claim
collabor
attitud
also
shown
abbvi
march
inform
due
current
health
emerg
would
stop
enforc
kaletra
patent
anywher
world
well
relat
treatment
hiv
wuhan
institut
virolog
brightgen
entiti
criticis
gilead
came
fire
version
remdesivir
obtain
march
orphan
drug
design
us
food
drug
administr
us
orphan
drug
act
design
give
sevenyear
market
exclus
period
well
tax
incent
pharmaceut
compani
produc
medicin
rare
diseas
impact
fewer
peopl
gilead
reprimand
appli
statu
thu
seek
exclus
right
despit
call
solidar
face
pandem
critic
gilead
inform
public
request
rescind
orphan
drug
design
previous
mention
one
may
argu
behaviour
ethic
questionableand
particular
patent
system
use
make
access
drug
difficult
especi
pandem
realli
justifi
ip
law
use
way
limit
avail
medicin
aim
increas
profit
time
health
emerg
moment
crisi
teach
us
clear
lesson
matter
philosoph
justif
ip
egoist
theori
incap
offer
convinc
argument
ground
ip
protect
effect
theori
consid
person
gain
term
existenti
selfrealis
econom
gain
legitim
sourc
ethic
defenc
ip
overarch
reason
case
conflict
individu
societ
wellb
appear
unten
pandem
show
essenti
interconnected
human
be
commun
uniti
individu
happi
becom
possibl
case
certain
level
welfar
collect
share
sens
plausibl
justif
ip
protect
must
address
relationship
individu
collect
need
concern
utilitarian
offer
argument
favour
ip
recognis
egoist
motiv
though
within
larger
altruist
framework
societ
util
function
ultim
goal
practic
tradit
version
argument
suggest
incent
author
inventor
instrument
maximis
social
util
key
principl
utilitarian
ethic
theori
sens
ip
protect
reward
innov
stimul
invest
time
invent
creativ
activ
turn
favour
optim
social
util
reward
justifi
term
good
indirectli
bring
whole
societi
view
therefor
person
gain
simpli
mean
higher
purpos
clearli
utilitarian
approach
fit
perfectli
pharmaceut
industri
incentivefocus
narr
patent
drug
avail
researchanddevelop
effort
discourag
tradit
form
utilitarian
show
limit
insofar
tend
identifi
innov
individu
subject
either
person
institut
compani
howev
effort
scientif
commun
time
crisi
clearli
show
process
discoveri
often
distribut
may
well
profit
collabor
differ
entiti
sens
innov
may
well
collect
rather
individu
subject
activ
protect
therefor
among
less
obviou
implic
altruist
justif
ip
follow
ip
establish
favour
condit
collabor
exchang
speed
process
scientif
discoveri
often
difficult
balanc
two
oppos
forc
aid
hiv
crisi
alreadi
show
us
patent
law
may
use
oppos
polici
adopt
democrat
elect
govern
balanc
patent
right
make
drug
afford
inde
group
pharmaceut
compani
took
south
african
govern
court
tri
stop
introduc
legisl
aim
reduc
price
medicin
main
object
south
african
medicin
act
arbitrarili
reduc
patent
protect
legal
action
abandon
old
recent
disput
behaviour
teach
us
ip
protect
particular
patent
regim
must
manag
great
care
well
willing
occasion
set
asid
financi
consider
favour
ethic
moral
concern
especi
come
face
unpreced
global
health
emerg
pandem
ip
law
certainli
crucial
incentivis
develop
often
vital
drug
far
perfect
may
well
requir
adjust
reform
meet
overarch
public
interest
solut
erod
mutual
trust
requir
make
intern
public
health
cooper
work
